A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
← catalyst calendarNCT06008093 · readout in 65 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
103actual
Sites
47
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-04 | actual | When the study began enrolling |
| Primary completion | 2026-10-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-28 | estimated | The whole study's end, after follow-up |
| First posted | 2023-08-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: Durvalumab — also filed as MEDI4736 & IMFINZI®
- Drug: Tremelimumab — also filed as IMJUDO®
- Drug: Pemetrexed — also filed as Background Platinum-based Chemotherapy
- Drug: Pembrolizumab
- Drug: Carboplatin — also filed as Background Platinum-based Chemotherapy
- Drug: Cisplatin — also filed as Background Platinum-based Chemotherapy
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS) in randomized participants
measured From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
PFS at 6 months
measured From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
PFS at 12 months
measured From randomization until death, withdrawal of consent, or the end of the study (approximately 48 months)
Publications
- PMID 41209621 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed